Wuhan Constant Science & Technology Co., Ltd. entered into an agreement to acquire 26.5% stake in Guangzhou Junsun Medical Technology Co Ltd from Guanhao Biotech Co.,Ltd. for CNY 1.
October 24, 2019
Share
Wuhan Constant Science & Technology Co., Ltd. entered into an agreement to acquire 26.5% stake in Guangzhou Junsun Medical Technology Co Ltd from Guanhao Biotech Co.,Ltd. (SZSE:300238) for CNY 1 on October 25, 2019. Under the terms, Guangzhou Junsun Medical Technology reported total assets worth CNY 20.2 million, net assets worth CNY 4.6 million, revenue worth CNY 0.3 million and net loss worth 2.8 million. The transaction has been approved by the 4th Board of Directors in the 18th meeting on October 25, 2019.
Guanhao Biotech Co., Ltd. is a China-based company principally engaged in the research, development, production and distribution of regeneration medical materials and medical implanted devices. The Company primarily provides biological dura mater patches, chest general surgery department patching membranes (type P) and (type B), asepsis biological wound-surface protection membranes, type B dura matrix, intraocular lens as well as agent products. The Company is also engaged in provision of related technological services.
Wuhan Constant Science & Technology Co., Ltd. entered into an agreement to acquire 26.5% stake in Guangzhou Junsun Medical Technology Co Ltd from Guanhao Biotech Co.,Ltd. for CNY 1.
GUANHAO BIOTECH CO.,LTD. 
